[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fuchs\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fuchs":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100460465","phase-3-descemet-endothelial-thickness-comparison-trial-ii-100460465",false,"NCT05275972","Descemet Endothelial Thickness Comparison Trial II","Descemet Endothelial Thickness Comparison Trials (DETECT I & II)","DETECT II","Inclusion Criteria:\n\n* Dysfunctional endothelium from FECD with few guttata extending beyond 4.5 mm\n* Peripheral endothelial cell count \\>1000 cells\u002Fmm2 in at least one quadrant\n* Good surgical candidate for either procedure as determined by the surgeon\n* Willingness to participate\n* Age greater than 18 years\n\nExclusion Criteria:\n\n* Aphakia, anterior chamber IOL or scleral fixated IOL in study eye prior to or anticipated during EK\n* Pre-operative central sub-epithelial or stromal scarring that the investigator believes is visually significant and could impact post-operative stromal clarity assessment\n* Other primary endothelial dysfunction such as PPMD\n* Visually significant optic nerve or macular pathology\n* Hypotony (Intraocular pressure \\\u003C10mmHg)\n* Any prior intraocular surgery other than cataract surgery\n* \\>3 clock hours of ANY anterior or posterior synechiae\n* \\>1 quadrant of stromal corneal vascularization\n* Inability to comply with post-operative instructions (i.e. unable to position)\n* Pregnancy","ALL","18 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.",[27,28,29],"Fuchs","Fuchs Dystrophy","Fuchs' Endothelial Dystrophy","RECRUITING","2026-05-06",{"date":33,"type":34},"2026-05-08","ACTUAL",{"date":36,"type":34},"2023-01-23",{"date":38,"type":21},"2028-11-30",{"name":40,"class":41},"Stanford University","OTHER",8,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":5},"100594841","phase-2-dt-168-in-keratoplasty-patients-with-fuchs-endothelial-corneal-dystrophy-100594841","NCT07024693","DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy","A Phase 2, Multicenter, Open-Label Study to Assess the Pharmacodynamics, Safety, and Tolerability of DT-168 Ophthalmic Solution in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Keratoplasty","Inclusion Criteria:\n\n* Participant is scheduled to undergo a keratoplasty for management of FECD independent of this study.\n* ≥30 years of age (inclusive).\n* Documented diagnosis of FECD in the study eligible eye.\n* Confirmation of positive TCF4 allele 18.1 CTG expansion in at least one allele.\n* Capable of giving signed informed consent.\n\nExclusion Criteria:\n\n* Any ocular or medical condition in the study eligible eye which is clinically significant or would confound study results or data interpretation.\n* Any clinically significant medical, nonmedical, and psychiatric disorders that could put the participant at higher risk for participation in the study, impair the participant's ability to participate in the study, or interfere with interpretation of the participant's study results, in the opinion of the investigator.\n* Concurrent or anticipated need for treatment for FECD, eg, Muro 128 (2% or 5%) during the course of the study in the study eye. Provided the subject undergoes a washout of Muro drops for at least 24 hours prior to the Baseline Visit, they will not be excluded.\n* Concurrent or anticipated use of topical corticosteroids in the study eye.\n* Concurrent use with Rhopressa®, Rocklatan®, or any other ocular Rho Kinase inhibitor.\n* Known contraindication, allergy, or hypersensitivity to any of the treatments, anesthetics, or diagnostic agents or components thereof which may be used during the study.\n* Use of contact lenses in the study eye within 7 days prior to the Baseline Visit or planned use during the study.\n* Recent (within 30 days of the Screening Visit) or ongoing participation in any other investigational interventional clinical study.\n* Female participant is pregnant, planning a pregnancy, or breast-feeding.\n* Participant is unwilling to comply with the contraceptive requirements, as per protocol.","30 Years",{"count":52,"type":21},28,[54],"PHASE2","The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.",[57,27],"Fuchs Endothelial Corneal Dystrophy","2025-12-24",{"date":60,"type":34},"2025-12-29",{"date":62,"type":34},"2025-07-30",{"date":64,"type":21},"2026-12",{"name":66,"class":67},"Design Therapeutics, Inc.","INDUSTRY"]